GlassScriptPhysician profile
Katy Ticona
NPI 1669867966
$8,244.00
in general payments reported to CMS, 2019-2025
64 companies · $1,701 in 2025
The $1,701 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.63 · 2020: $99.45 · 2021: $29.93 · 2022: $1,860 · 2023: $2,148 · 2024: $2,357 · 2025: $1,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,064 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,064.28 |
| Education | $141.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $789.94 | 2022-2025 | |
| Celgene Corporation | $539.85 | 2022-2025 | Reblozyl, Pomalyst |
| Incyte Corporation | $508.55 | 2020-2025 | Monjuvi, Jakafi, Pemazyre |
| Eisai INC. | $495.36 | 2020-2024 | |
| Daiichi Sankyo INC. | $475.14 | 2020-2025 | Enhertu, Injectafer |
| Lilly USA, LLC | $421.90 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $410.43 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $399.91 | 2022-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $294.47 | 2022-2025 | Keytruda, Lynparza |
| Gilead Sciences, INC. | $268.89 | 2022-2025 | Trodelvy |
| Beigene USA, INC. | $224.81 | 2022-2024 | Brukinsa |
| Janssen Biotech, INC. | $214.53 | 2022-2025 | Carvykti, Rybrevant, Erleada |
| Genzyme Corporation | $178.96 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $178.48 | 2025 | Enhertu, Imfinzi, Lynparza |
| Pharmacosmos Therapeutics INC. | $175.37 | 2022-2025 | Monoferric, Cosela |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $157.13 | 2022-2023 | Padcev, Adcetris, Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $137.37 | 2021-2025 | Iclusig, Ninlaro |
| Jazz Pharmaceuticals INC. | $130.29 | 2022-2024 | |
| Pharmaessentia USA Corporation | $115.91 | 2024-2025 | Besremi |
| Glaxosmithkline, LLC. | $106.12 | 2023-2025 | Ojjaara |
| Aveo Pharmaceuticals, INC. | $100.56 | 2022 | |
| Puma Biotechnology, INC. | $80.57 | 2022-2024 | |
| Array Biopharma INC | $72.10 | 2023-2025 | Lorbrena, Mektovi, Braftovi |
| Fennec Pharmaceuticals, INC. | $70.81 | 2024 | Pedmark |
| E.R. Squibb & Sons, L.L.C. | $68.93 | 2020-2023 | Opdivo |
| Janssen Scientific Affairs, LLC | $67.92 | 2025 | Darzalex, Tecvayli, Talvey |
| Sun Pharmaceutical Industries INC. | $65.79 | 2023-2025 | Odomzo, Yonsa |
| Exelixis INC. | $61.61 | 2022-2023 | Cabometyx |
| Tempus Ai, INC | $59.53 | 2024 | Xt Cdx |
| Legend Biotech USA INC. | $59.01 | 2024-2025 | Carvykti |
| Organon LLC | $58.47 | 2022-2023 | Ontruzant |
| Agios Pharmaceuticals, INC. | $58.21 | 2025 | Pyrukynd |
| Beone Medicines USA, INC. | $57.80 | 2025 | Brukinsa |
| Cti Biopharma Corp. | $56.68 | 2022-2023 | Vonjo |
| Sobi, INC | $54.44 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.89 | 2022-2023 | Gilotrif |
| Novocure INC. | $51.82 | 2025 | Optune Gio, Optune Lua (Novottf-200t) |
| Stemline Therapeutics INC. | $51.36 | 2023-2025 | Orserdu |
| Sumitomo Pharma America, INC. | $50.32 | 2024 | Orgovyx |
| Servier Pharmaceuticals LLC | $49.86 | 2022-2023 | |
| Amgen INC. | $48.77 | 2022 | |
| Alexion Pharmaceuticals, INC. | $48.63 | 2019 | |
| Kyowa Kirin, INC. | $48.46 | 2024-2025 | Poteligeo |
| Accord Healthcare, INC. | $47.44 | 2024 | |
| Telix Pharmaceuticals | $42.97 | 2023-2024 | Illuccix |
| Deciphera Pharmaceuticals INC. | $42.94 | 2022-2023 | Qinlock |
| Caris Mpi, INC. | $41.37 | 2025 | Mi Cancer Seek |
| Alnylam Pharmaceuticals INC. | $40.09 | 2024 | Onpattro |
| Genentech USA, INC. | $39.80 | 2023 | Perjeta, Phesgo, Venclexta |
| Global Blood Therapeutics, INC. | $34.09 | 2022 | |
| Morphosys, US INC. | $33.27 | 2022-2023 | Monjuvi |
| Dendreon Pharmaceuticals LLC | $31.49 | 2024 | Provenge |
| Foundation Medicine, INC. | $29.42 | 2023 | |
| Kite Pharma, INC. | $29.31 | 2025 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $28.70 | 2023 | Imbruvica |
| Ge Healthcare | $27.98 | 2022 | |
| Azurity Pharmaceuticals, INC. | $24.50 | 2024 | Vivimusta |
| Abbvie INC. | $24.19 | 2025 | |
| Emd Serono, INC. | $22.43 | 2024 | |
| Myovant Sciences INC. | $22.00 | 2022 | |
| Karyopharm Therapeutics INC. | $21.44 | 2022 | |
| Taiho Oncology, INC. | $18.15 | 2025 | |
| Verity Pharmaceuticals INC. | $18.05 | 2023 | Trelstar |
| Rigel Pharmaceuticals, INC. | $5.42 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katy Ticona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.